Dr. Patricia N. Hurter has been the Chief Executive Officer of Lyndra Therapeutics Inc. since September 2019. Dr. Hurter was a Senior Vice President at Vertex from 2011 to 2019, during which time her responsibilities grew to include all CMC and preclinical development activities of Vertex’s R&D portfolio, as well as the internal GMP manufacturing facility that provides drug substance and product for clinical development and commercial supply. From 2013 to 2014, she served as Interim Head of Global Regulatory Affairs at Vertex and oversaw the submission of the new drug application for Orkambi®, as well as several label expansions for Kalydeco®. She played a leadership role in the development and commercialization of five therapies for Vertex: Incivek®, Kalydeco®, Orkambi®, Symdeko®, and Trikafta®. Prior to joining Vertex in 2004, Dr. Hurter was Director of Formulation Design and Characterization for Merck where she was a key member of the early development team for Januvia®, a treatment for Type II diabetes. She holds a Ph.D. in chemical engineering from the Massachusetts Institute of Technology, an M.S. in mechanical engineering from West Virginia University, and a B.Sc. in chemical engineering from the University of KwaZulu-Natal in Durban, South Africa.
Chief Executive Officer